Traxion Sab De Cv Ord Shs GRPOF

RE:RE:RE:Potential "side" trial for TBP?

[Stocknurse]

Hi all, 

I love this thread as it hits on exactly why I decided to invest in Tetra Bio Pharma for the long run- we need companies that will focus on differentiating medical cannabis from recreational. What Tetra Bio Pharma appears to be doing is much larger that the DIN- it is about obtaining the evidence required for regulated professionals to be able to understand and successfully incorporate proven cannabinoid-based drugs into a patient plan of care. 

An example of current expectations for physicians prescribing cannabis for medical purposes can be found here on page 20: https://cpsm.mb.ca/cjj39alckF30a/wp-content/uploads/ByLaws/By-Law-11.pdf. (NOTE: each jurisdiction is likely different)

An exert includes: 
Prior to authorizing marijuana for a patient, a member must: (a) make a conventional diagnosis using the principles of good medical care set out in s. 2 of this by-law; (b) ensure that other conventional therapies have been tried for the patient’s condition; (c) discuss with the patient all potential risks and benefits and the lack of clear scientific evidence supporting the efficacy of the proposed treatment; (d) document on the patient record the discussions with the patient and the medical reasons for which the marijuana is authorized.
 
*If we can prove that specific cannaboid-based therapies are effective for specific conditions they can move towards being considered conventional therapies and the above highlighted in yellow becomes obsolete.

Differentiating medical from recreational: an individual who purchases recreational cannabis "hoping it is effective" may be wasting their money or increasing their risk of a negative outcome as they may not recieve the information needed to make an informed choice within the context of their complete care plan. They also could risk having less access as they transition between practice settings as their own recreational intervention may be missed during medication reconciliation.

Many patients have very complex care plans with a variety of regulated and unregulated care providers involved in care across practice settings.

10 years from now:

Will cannaboid- based therapies be taught at the undergraduate level (including teaching of how to administrater- which is where a standardised device like ppp001 would decomplicate things)? Will a patient be able to pick up all their cannaboid-based therapies at Shoppers Drugmart (or their pharmacy of choice)  along with their bubblepacked medications, liquid medications etc. all in one go? Will teaching/assistance/administration be provided by health care providers across all settings (hospital/community/home)? I think so, and I think Tetra Bio Pharma is positioning itself in the center of the shift to creating conventional cannaboid-based therapies.  GLTA.